This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Catamaran Corporation Reduces Overall Drug Trend To 2.6 Percent In 2012

Stocks in this article: CTRX

Record-setting generic dispensing rate, clinical strategy reduced drug trend for members and clients year-over-year

LISLE, IL, June 12, 2013 /PRNewswire/ - Catamaran Corp. (NASDAQ: CTRX) (TSX: CCT), a leading provider of pharmacy benefit management (PBM) services and technology, recently released its 2012 Informed Trends™ report, revealing a 0.9 percentage point year-over-year reduction in overall drug trend from 3.5 percent (2011) to 2.6 percent (2012). Catamaran's record-setting generic dispensing rate of 81.9 percent - a 5 percentage point increase over 2011 - contributed to a 1.2 percent decrease in traditional drug spend.

The report, Healthcare HD - The Power of High Definition, also found that highly managed clients - those that utilize Catamaran's full scope of clinical, communications and channel-management programs - experienced a 1 percent drug trend compared to 2.6 percent for the commercial book-of-business.

"The availability of new generic medications coupled with Catamaran's customized programs and personalized interventions generated cost savings for clients across all segments," said Mark Thierer, Chairman and CEO of Catamaran. "While we are always focused on maximizing value for clients' and members' healthcare dollars, Catamaran is moving beyond price of medications, channel and distribution to focus on the power of data and insights to improve the quality of care, creating healthier communities across the nation."

Specialty medications accounted for approximately 20 percent of the overall U.S. drug market by volume in 2012. To manage this high-cost market segment expected to increase to 23 percent of total global volume by 2018, Catamaran launched its specialty brand BriovaRx™ last year, delivering savings to clients and hands-on, individualized care to patients.

"An increase in chronic and complex diseases points to the need to encourage preventive health measures," said Sumit Dutta, Senior Vice President and Chief Medical Officer at Catamaran. "Catamaran's personalized approach engages at-risk members at the right time with the right intervention driving better healthcare decisions and financial outcomes."

Healthcare HD - The Power of High Definition, the theme of the report, highlights Catamaran's clinical approach of driving national strategies, shaped for local differences and personalized for individual patients.  National best practices combined with Catamaran's expertise in technology and analytics form the foundation for Catamaran's clinical programs.  Regional presence, local partnerships and flexible technology create connections in the communities Catamaran serves and enable it to customize programs to meet specific client needs.  Individual risk scores and tailored messaging and interventions engage members to take charge of their health.  Catamaran employs all three levels as a proven model to lower pharmacy trend and produce the best outcomes.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs